期刊文献+

拉米夫定联合复方甘草酸苷治疗乙肝后肝硬化疗效观察

下载PDF
导出
摘要 目的探讨拉米夫定联合复方甘草酸苷治疗乙肝后肝硬化的疗效。方法将120例乙肝后肝硬化患者随机分为2组:2组均给予拉米夫定100 mg每日1次口服,治疗组在此基础上服用复方甘草酸苷50 mg,每日3次,2组疗程均为6个月。结果疗程结束时,治疗组血清ALT复常率、血清HBeAg阴转率及HBV-DNA阴转率均明显高于对照组。停药6个月后,治疗组上述指标仍明显高于对照组。结论拉米夫定联合复方甘草酸苷能有效抑制乙肝病毒的复制,是治疗乙肝后肝硬化安全有效的方法 。
出处 《现代中西医结合杂志》 CAS 2010年第28期3595-3596,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献5

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14005
  • 2拉米夫定临床应用专家组 ,万谟彬.2004年拉米夫定临床应用专家共识[J].中华肝脏病杂志,2004,12(7):425-428. 被引量:257
  • 3Tanaka N,Horiuchi A,Yamaura T,et al.Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections[J].J Gastroenterol,2009,44(6):577-582.
  • 4Tsuruoka N,Abe K,Wake K,et al.Hepatic protection by glycyrrhizin and inhibition of iNOS expression in concanavalin A-induced liver injury in mice[J].Inflamm Res,2009,58(9):593-599.
  • 5Moro T,Shimoyama Y,Kushida M.Glycyrrhizin and its metabolite inhibit Smad-mediated type I collagen gene transcription and suppress experimental murine liver fibrosis[J].Life Sci,2008,83(15/16):531-539.

二级参考文献24

  • 1Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 2Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 3Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 4Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 5Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 7Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 8Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 9Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
  • 10Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Seminars in liver disease. 2003 23: 89-100.

共引文献14151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部